Cody A Rutledge1, Fu Siong Ng2, Matthew S Sulkin2, Ian D Greener3, Artem M Sergeyenko3, Hong Liu3, Joanna Gemel4, Eric C Beyer4, Ali A Sovari3, Igor R Efimov2, Samuel C Dudley5. 1. Department of Physiology, University of Illinois at Chicago, Chicago, Illinois; Lifespan Cardiovascular Institute, the Warren Alpert School of Medicine of Brown University, and the Providence Veterans Administration Medical Center, Providence. Rhode Island. 2. Department of Biomedical Engineering, Washington University, St. Louis, Missouri. 3. Lifespan Cardiovascular Institute, the Warren Alpert School of Medicine of Brown University, and the Providence Veterans Administration Medical Center, Providence. Rhode Island. 4. Department of Pediatrics, University of Chicago, Chicago, Illinois. 5. Lifespan Cardiovascular Institute, the Warren Alpert School of Medicine of Brown University, and the Providence Veterans Administration Medical Center, Providence. Rhode Island. Electronic address: samuel_dudley@brown.edu.
Abstract
OBJECTIVES: The aim of this study was to evaluate the role of tyrosine kinase cellular-Src (c-Src) inhibition on connexin43 (Cx43) regulation in a mouse model of myocardial infarction (MI). BACKGROUND: MI is associated with decreased expression of Cx43, the principal gap junction protein responsible for propagating current in ventricles. Activated c-Src has been linked to Cx43 dysregulation. METHODS: MI was induced in 12-week-old mice by coronary artery occlusion. MI mice were treated with c-Src inhibitors (PP1 or AZD0530), PP3 (an inactive analogue of PP1), or saline. Treated hearts were compared to sham mice by echocardiography, optical mapping, telemetry electrocardiographic monitoring, and inducibility studies. Tissues were collected for immunoblotting, quantitative polymerase chain reaction, and immunohistochemistry. RESULTS: Active c-Src was elevated in PP3-treated MI mice compared to sham at the scar border (280%, p = 0.003) and distal ventricle (346%, p = 0.013). PP1 treatment restored active c-Src to sham levels at the scar border (86%, p = 0.95) and distal ventricle (94%, p = 1.0). PP1 raised Cx43 expression by 69% in the scar border (p = 0.048) and by 73% in the distal ventricle (p = 0.043) compared with PP3 mice. PP1-treated mice had restored conduction velocity at the scar border (PP3: 32 cm/s, PP1: 41 cm/s, p < 0.05) and lower arrhythmic inducibility (PP3: 71%, PP1: 35%, p < 0.05) than PP3 mice. PP1 did not change infarct size, electrocardiographic pattern, or cardiac function. AZD0530 treatment demonstrated restoration of Cx43 comparable to PP1. CONCLUSIONS: c-Src inhibition improved Cx43 levels and conduction velocity and lowered arrhythmia inducibility after MI, suggesting a new approach for arrhythmia reduction following MI.
OBJECTIVES: The aim of this study was to evaluate the role of tyrosine kinase cellular-Src (c-Src) inhibition on connexin43 (Cx43) regulation in a mouse model of myocardial infarction (MI). BACKGROUND: MI is associated with decreased expression of Cx43, the principal gap junction protein responsible for propagating current in ventricles. Activated c-Src has been linked to Cx43 dysregulation. METHODS: MI was induced in 12-week-old mice by coronary artery occlusion. MI mice were treated with c-Src inhibitors (PP1 or AZD0530), PP3 (an inactive analogue of PP1), or saline. Treated hearts were compared to sham mice by echocardiography, optical mapping, telemetry electrocardiographic monitoring, and inducibility studies. Tissues were collected for immunoblotting, quantitative polymerase chain reaction, and immunohistochemistry. RESULTS: Active c-Src was elevated in PP3-treated MI mice compared to sham at the scar border (280%, p = 0.003) and distal ventricle (346%, p = 0.013). PP1 treatment restored active c-Src to sham levels at the scar border (86%, p = 0.95) and distal ventricle (94%, p = 1.0). PP1 raised Cx43 expression by 69% in the scar border (p = 0.048) and by 73% in the distal ventricle (p = 0.043) compared with PP3 mice. PP1-treated mice had restored conduction velocity at the scar border (PP3: 32 cm/s, PP1: 41 cm/s, p < 0.05) and lower arrhythmic inducibility (PP3: 71%, PP1: 35%, p < 0.05) than PP3 mice. PP1 did not change infarct size, electrocardiographic pattern, or cardiac function. AZD0530 treatment demonstrated restoration of Cx43 comparable to PP1. CONCLUSIONS:c-Src inhibition improved Cx43 levels and conduction velocity and lowered arrhythmia inducibility after MI, suggesting a new approach for arrhythmia reduction following MI.
Authors: M A Beardslee; D L Lerner; P N Tadros; J G Laing; E C Beyer; K A Yamada; A G Kléber; R B Schuessler; J E Saffitz Journal: Circ Res Date: 2000-10-13 Impact factor: 17.367
Authors: Zhongju Lu; Chia-Yen C Wu; Ya-Ping Jiang; Lisa M Ballou; Chris Clausen; Ira S Cohen; Richard Z Lin Journal: Sci Transl Med Date: 2012-04-25 Impact factor: 17.956
Authors: K Soejima; M Suzuki; W H Maisel; C B Brunckhorst; E Delacretaz; L Blier; S Tung; H Khan; W G Stevenson Journal: Circulation Date: 2001-08-07 Impact factor: 29.690
Authors: Benjamin F Remo; Jiaxiang Qu; Frank M Volpicelli; Steven Giovannone; Daniel Shin; Joshua Lader; Fang-Yu Liu; Jie Zhang; Danielle S Lent; Gregory E Morley; Glenn I Fishman Journal: Circ Res Date: 2011-04-28 Impact factor: 17.367
Authors: Ali A Sovari; Shahriar Iravanian; Elena Dolmatova; Zhe Jiao; Hong Liu; Shadi Zandieh; Vibhash Kumar; Kun Wang; Kenneth E Bernstein; Marcelo G Bonini; Heather S Duffy; Samuel C Dudley Journal: J Am Coll Cardiol Date: 2011-11-22 Impact factor: 24.094
Authors: Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz Journal: Pharmacol Rev Date: 2017-10 Impact factor: 25.468
Authors: Li Zheng; Hanjun Li; Andrew Cannon; Andrew J Trease; Gaelle Spagnol; Hong Zheng; Stanley Radio; Kaushik Patel; Surinder Batra; Paul L Sorgen Journal: J Mol Cell Cardiol Date: 2018-11-15 Impact factor: 5.000
Authors: Man Liu; Hong Liu; Preethy Parthiban; Gyeoung-Jin Kang; Guangbin Shi; Feng Feng; Anyu Zhou; Lianzhi Gu; Courtney Karnopp; Elena G Tolkacheva; Samuel C Dudley Journal: J Clin Invest Date: 2021-09-15 Impact factor: 14.808